As the diagnosis and management of systemic lupus erythematosus (SLE) can be challenging, reclassification of SLE on the basis of biomarker data provides novel insights. Definitions of antinuclear antibodies and attention to SMAARTT criteria (specificity – sensitivity, measurable, actionable, added value, realistic, titres, timely) are needed to translate these new analytical frameworks into real-time clinical use.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Challenges and Advances in SLE Autoantibody Detection and Interpretation
Current Treatment Options in Rheumatology Open Access 07 May 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tsokos, G. C., Lo, M. S., Costa, R. P. & Sullivan, K. E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 12, 716–730 (2016).
Pisetsky, D. S., Rovin, B. H. & Lipsky, P. E. Biomarkers as entry criteria for clinical trials of new therapies for systemic lupus erythematosus: the example of ANA and anti-DNA. Arthritis Rheumatol. 69, 487–493 (2017).
Artim-Esen, B. et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J. Rheumatol. 41, 1304–1310 (2014).
To, C. H. & Petri, M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 52, 4003–4010 (2005).
Pacheco, Y. et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J. Transl Med. 15, 239–1345 (2017).
Lewis, M. J. et al. Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus. J Autoimmun. https://doi.org/10.1016/j.jaut.2018.02.009 (2018).
Pisetsky, D. S. Antinuclear antibody testing - misunderstood or misbegotten? Nat. Rev. Rheumatol. 13, 495–502 (2017).
Mahler, M. Lack of standardisation of ANA and implications for drug development and precision medicine. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-213374 (2018).
Barturen, G., Beretta, L., Cervera, R., Van, V. R. & Alarcon-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 75–93 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.M. is employed at Inova Diagnostics manufacturing and selling autoantibody assays. M.J.F. is a consultant to and/or has received research gifts in kind from Alexion Canada, Euroimmun GmbH and Inova Diagnostics.
Rights and permissions
About this article
Cite this article
Fritzler, M.J., Mahler, M. Redefining systemic lupus erythematosus — SMAARTT proteomics. Nat Rev Rheumatol 14, 451–452 (2018). https://doi.org/10.1038/s41584-018-0035-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0035-3
This article is cited by
-
Challenges and Advances in SLE Autoantibody Detection and Interpretation
Current Treatment Options in Rheumatology (2019)